2019
DOI: 10.3390/ijms20061388
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy of Valganciclovir Treatment Depends on the Severity of Hearing Dysfunction in Symptomatic Infants with Congenital Cytomegalovirus Infection

Abstract: Although earlier studies have shown that antiviral treatment regimens using valganciclovir (VGCV) improved hearing function in some infants with congenital cytomegalovirus (CMV) infection; its efficacy on the severity of hearing dysfunction is unclear. We conducted a prospective study among 26 infants with congenital CMV infections from 2009 to 2018. Oral VGCV (32 mg/kg/day) was administered for 6 weeks (November 2009 to June 2015; n = 20) or 6 months (July 2015 to March 2018, n = 6). Hearing function was eval… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

6
48
0
2

Year Published

2019
2019
2025
2025

Publication Types

Select...
7
2

Relationship

2
7

Authors

Journals

citations
Cited by 32 publications
(58 citation statements)
references
References 19 publications
6
48
0
2
Order By: Relevance
“…Brain CT abnormalities included intracranial calcifications, ventricular dilation, white matter abnormalities, and cortical dysplasia [10]. CCMVI was considered “symptomatic” if at least one of the following symptoms was present: thrombocytopenia, liver dysfunction, microcephaly, hearing loss, head image abnormality, ophthalmic abnormality, and SGA [15].…”
Section: Methodsmentioning
confidence: 99%
“…Brain CT abnormalities included intracranial calcifications, ventricular dilation, white matter abnormalities, and cortical dysplasia [10]. CCMVI was considered “symptomatic” if at least one of the following symptoms was present: thrombocytopenia, liver dysfunction, microcephaly, hearing loss, head image abnormality, ophthalmic abnormality, and SGA [15].…”
Section: Methodsmentioning
confidence: 99%
“…The DQ was assessed using the Kyoto Scale of Psychological Development [18]. All CCMVI infants with clinical symptoms and a few CCMVI infants without clinical symptoms were admitted to our hospital within 1 month of age and were treated with oral valganciclovir (VGCV) 32 mg/kg/day for 6 weeks in 2009–2015, and for 6 months since 2016, as previously described [17, 19, 20].…”
Section: Methodsmentioning
confidence: 99%
“…Furthermore, Valganciclovir has been reported to improve hearing outcomes in symptomatic infants with congenital CMV infection [ 76 ]. However, the efficacy of Valganciclovir depends on the severity of hearing abnormalities [ 77 ]. Hearing aids and cochlear implantation are usually recommended in cases where antivirals do not improve CMV-triggered SNHL.…”
Section: Potential Molecular Origins Of Virus-induced Hearing Lossmentioning
confidence: 99%